Literature DB >> 31326380

Fixed Drug Eruption to Biologics and Role of Lesional Patch Testing.

Philip H Li1, Timothy J Watts2, Ho-Yin Chung3, Chak-Sing Lau3.   

Abstract

Entities:  

Year:  2019        PMID： 31326380     DOI： 10.1016/j.jaip.2019.06.028

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  4 in total

1.  Prevalence and Impact of Reported Drug Allergies among Rheumatology Patients.

Authors:  Shirley Chiu Wai Chan; Winnie Wan Yin Yeung; Jane Chi Yan Wong; Ernest Sing Hong Chui; Matthew Shing Him Lee; Ho Yin Chung; Tommy Tsang Cheung; Chak Sing Lau; Philip Hei Li
Journal:  Diagnostics (Basel)       Date:  2020-11-09

2.  Galcanezumab-induced fixed drug eruption.

Authors:  Skylar Klager; Marina Khalil; Kenneth Shulman; Naveed Sami
Journal:  JAAD Case Rep       Date:  2021-01-30

3.  Delayed-type drug eruption to phenazopyridine (pyridium) confirmed with patch testing.

Authors:  Winnie W Y Yeung; Christina S M Wong; Wai-Yan Leung; Philip H Li
Journal:  Asia Pac Allergy       Date:  2022-01-25

Review 4.  The Role of Patch Testing in Evaluating Delayed Hypersensitivity Reactions to Medications.

Authors:  Carina M Woodruff; Nina Botto
Journal:  Clin Rev Allergy Immunol       Date:  2022-02-03       Impact factor: 10.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.